TScan Therapeutics, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1287533,
    "name": "TScan Therapeutics, Inc.",
    "stock_name": "TScan Therapeutics, Inc.",
    "full_name": "TScan Therapeutics, Inc.",
    "name_url": "stocks-analysis/tscan-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.09",
    "chg": 0.14,
    "chgp": "14.47%",
    "dir": 1,
    "prev_price": "0.95",
    "mcapval": "106.69",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US89854M1018",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "320.91 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/tscan-therapeutics-inc-1287533-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "TScan Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/tscan-therapeutics-forms-golden-cross-signaling-potential-bullish-breakout-3619693",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TScanTherapeuti_goldencross_3619693.png",
        "date": "2025-10-14 15:32:36",
        "description": "TScan Therapeutics, Inc. has recently achieved a Golden Cross, indicating potential upward momentum in its stock. Despite a challenging year, the company has shown resilience with a notable monthly increase, outperforming the S&P 500. Investors are watching closely to see if this technical development can drive further growth."
      },
      {
        "title": "Is TScan Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-tscan-therapeutics-inc-technically-bullish-or-bearish-3547865",
        "imagepath": "",
        "date": "2025-09-20 20:04:45",
        "description": "As of 1 July 2025, the technical trend for TScan Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bullish stance weekly, contrasting with a bearish monthly outlook. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish position on both weekly and monthly charts. \n\nThe stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -43.42% versus the S&P 500's 12.22%, and a one-year return of -68.95% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by mixed indicators across different timeframes...."
      },
      {
        "title": "Is TScan Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-tscan-therapeutics-inc-overvalued-or-undervalued-3544103",
        "imagepath": "",
        "date": "2025-09-20 18:37:54",
        "description": "As of 10 November 2021, the valuation grade for TScan Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued given its significant losses and the valuation ratios, including a Price to Book Value of 0.48, an EV to EBIT of 0.81, and an EV to EBITDA of 0.83, which suggest that the market may not be pricing in the risks adequately. \n\nIn comparison to its peers, TScan's EV to EBITDA ratio of 0.83 is more favorable than Heron Therapeutics, Inc.'s -199.2793, but still lags behind TriSalus Life Sciences, Inc.'s -6.9780. The company's recent stock performance has been poor, with a year-to-date return of -43.42% compared to the S&P 500's 12.22%, reinforcing the notion that TScan is currently overvalued in the market...."
      }
    ],
    "total": 7,
    "sid": "1287533",
    "stock_news_url": "https://www.marketsmojo.com/news/tscan-therapeutics-inc-1287533"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

TScan Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-14 15:32:36

TScan Therapeutics, Inc. has recently achieved a Golden Cross, indicating potential upward momentum in its stock. Despite a challenging year, the company has shown resilience with a notable monthly increase, outperforming the S&P 500. Investors are watching closely to see if this technical development can drive further growth.

Is TScan Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:04:45

As of 1 July 2025, the technical trend for TScan Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bullish stance weekly, contrasting with a bearish monthly outlook. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish position on both weekly and monthly charts. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -43.42% versus the S&P 500's 12.22%, and a one-year return of -68.95% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by mixed indicators across different timeframes....

Is TScan Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:37:54

As of 10 November 2021, the valuation grade for TScan Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued given its significant losses and the valuation ratios, including a Price to Book Value of 0.48, an EV to EBIT of 0.81, and an EV to EBITDA of 0.83, which suggest that the market may not be pricing in the risks adequately. In comparison to its peers, TScan's EV to EBITDA ratio of 0.83 is more favorable than Heron Therapeutics, Inc.'s -199.2793, but still lags behind TriSalus Life Sciences, Inc.'s -6.9780. The company's recent stock performance has been poor, with a year-to-date return of -43.42% compared to the S&P 500's 12.22%, reinforcing the notion that TScan is currently overvalued in the market....

View All News